Mar 27, 2025 11:58AM Ontario expects U.S. to lessen impact of auto tariffs on Canada, following Lutnick phone call - The Globe and Mail

Jan 23, 2025 03:01PM Tiziana Life Sciences (TLSA) Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025 08:59AM Tiziana Life Sciences (TLSA) not to engage in capital raising activities for the immediate future

Jan 22, 2025 04:31PM Tiziana Life Sciences (TLSA) Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Jan 10, 2025 08:03AM Tiziana Life Sciences (TLSA) Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

Jan 8, 2025 07:01AM Tiziana Life Sciences (TLSA) Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Dec 4, 2024 07:01AM Tiziana Life Sciences (TLSA) Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

Nov 19, 2024 07:02AM Tiziana Life Sciences (TLSA) Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

Oct 30, 2024 08:33AM Tiziana Life Sciences (TLSA) Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

Sep 19, 2024 07:02AM Tiziana Life Sciences (TLSA) Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

Aug 19, 2024 07:00AM Tiziana Life Sciences (TLSA) Appoints Ivor Elrifi as CEO

Aug 14, 2024 07:04AM Tiziana Life Sciences (TLSA) Regains Nasdaq Compliance

Jul 24, 2024 07:00AM Tiziana Life Sciences (TLSA) Granted FDA Fast Track Designation

Jun 28, 2024 11:02AM Tiziana Life Sciences (TLSA) Receives $3.4 Million in Non-Dilutive Funding

Jun 11, 2024 08:03AM Tiziana Life Sciences (TLSA) Announces FDA Acceptance of Fast Track Designation Submission for Treatment of Multiple Sclerosis